Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses recent updates on the use of CAR-T therapy in multiple myeloma and the value of these agents. Prof. Mohty first highlights the importance of having two CAR-T cells approved in the relapsed/refractory (R/R) setting, namely ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel). Following this, Prof. Mohty discusses important clinical trials in this space, including the KarMMa-3 trial (NCT03651128) and the CARTITUDE-4 trial (NCT04181827), and concludes by highlighting the value of novel GPRC5D and FcRH5-targeted agents. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the importance of testing for measurable residual disease (MRD) in patients with multiple myeloma. Dr Landgren first comments on the role that MRD may play as a clinical endpoint and how this may speed up drug development in the field, and then explains the possibility of using MRD to guide treatment decisions. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Gareth Morgan, MD, PhD; Rafael Fonseca, MD; and Thomas G. Martin, MD, discuss the diagnosis and upfront treatment of a 56-year-old man with stage International Scoring System-II multiple myeloma, including considerations for maintenance therapy.

In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France shares some key updates in multiple myeloma from the 2022 EHA meeting, drawing focus on the excitement surrounding bispecific antibodies. Prof. Mohty first discusses the impressive response rates observed with bispecifics in heavily pre-treated patients, and further highlights some findings from the MajesTEC-1 trial (NCT04557098). To conclude, Prof. Mohty comments on novel antigens being investigated and the promising results observed with anti-BCMA therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.